AR040110A1 - Formulaciones de fibrato en nanoparticulas - Google Patents

Formulaciones de fibrato en nanoparticulas

Info

Publication number
AR040110A1
AR040110A1 ARP030101837A ARP030101837A AR040110A1 AR 040110 A1 AR040110 A1 AR 040110A1 AR P030101837 A ARP030101837 A AR P030101837A AR P030101837 A ARP030101837 A AR P030101837A AR 040110 A1 AR040110 A1 AR 040110A1
Authority
AR
Argentina
Prior art keywords
fibrate
particles
less
nanoparticles
formulations
Prior art date
Application number
ARP030101837A
Other languages
English (en)
Original Assignee
Elan Pharma Int Ltd
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29586821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharma Int Ltd, Fournier Lab Ireland Ltd filed Critical Elan Pharma Int Ltd
Publication of AR040110A1 publication Critical patent/AR040110A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Composiciones de fibrato que tienen mejores perfiles farmacocinéticos y menor variabilidad saciedad-ayuno. Las partículas de fibrato de la composición tienen un tamano de partícula efectivo promedio inferior a aproximadamente 2000 nm. Reivindicación 1: Una composición estable de fibrato caracterizada porque comprende: (a) partículas de un fibrato o una sal del mismo, donde las partículas de fibrato tienen un tamano de partícula efectivo promedio inferior a aproximadamente 2000 nm; y (b) asociado con su superficie al menos un estabilizador de superficie, donde el estabilizador de superficie no es vitamina E derivatizada con polietilénglicol (PEG).
ARP030101837A 2002-05-24 2003-05-26 Formulaciones de fibrato en nanoparticulas AR040110A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38329402P 2002-05-24 2002-05-24
US10/370,277 US20030224058A1 (en) 2002-05-24 2003-02-21 Nanoparticulate fibrate formulations

Publications (1)

Publication Number Publication Date
AR040110A1 true AR040110A1 (es) 2005-03-16

Family

ID=29586821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101837A AR040110A1 (es) 2002-05-24 2003-05-26 Formulaciones de fibrato en nanoparticulas

Country Status (23)

Country Link
US (1) US20030224058A1 (es)
EP (1) EP1519715B1 (es)
JP (2) JP4395074B2 (es)
KR (3) KR101216853B1 (es)
CN (3) CN101797245B (es)
AR (1) AR040110A1 (es)
AU (2) AU2003301807B9 (es)
BR (1) BRPI0311275A2 (es)
CA (1) CA2487054C (es)
EA (2) EA012842B1 (es)
ES (1) ES2946493T3 (es)
IL (2) IL165332A0 (es)
MA (1) MA27250A1 (es)
MX (1) MXPA04011653A (es)
MY (1) MY143202A (es)
NO (1) NO20050224L (es)
NZ (1) NZ537324A (es)
PT (1) PT1519715T (es)
SG (1) SG159391A1 (es)
TN (1) TNSN04230A1 (es)
TW (1) TWI347198B (es)
UY (2) UY27822A1 (es)
WO (1) WO2004041250A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
DE60332212D1 (de) 2002-02-04 2010-06-02 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
RU2343905C2 (ru) * 2003-10-10 2009-01-20 Лайфсайкл Фарма А/С Твердые дозированные формы, включающие фибрат и статин
EP1680099B1 (en) * 2003-11-07 2009-04-15 JJ Pharma, Inc. Hdl-boosting combination therapy complexes
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
US20080031825A1 (en) * 2004-08-20 2008-02-07 Yisheng Chen Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate
US7339015B2 (en) * 2004-10-28 2008-03-04 The United States Of America As Represented By The Secretary Of The Navy Multifunctional self-decontaminating surface coating
BRPI0519088A2 (pt) * 2004-12-15 2008-12-23 Elan Pharma Int Ltd formulaÇÕes de tacrolimo nanoparticuladas
WO2006074218A2 (en) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
AU2006233061A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
KR20080002939A (ko) * 2005-04-12 2008-01-04 엘란 파마 인터내셔널 리미티드 나노입자형 퀴나졸린 유도체 제제
GB2442366A (en) * 2005-04-13 2008-04-02 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
WO2006084475A2 (en) * 2005-04-13 2006-08-17 Lifecycle Pharma A/S A tablet comprising a fibrate
JP2009511435A (ja) * 2005-09-28 2009-03-19 ディーエヌピー・カナダ・インコーポレーテッド 高脂血症の予防および治療のためのポリキトサミンとフィブレートの組み合わせ
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
IN2014MN00380A (es) * 2006-06-30 2015-06-19 Iceutica Pty Ltd
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
KR100767349B1 (ko) 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
ES2731881T3 (es) * 2007-09-25 2019-11-19 Formulex Pharma Innovations Ltd Composiciones que comprenden compuestos activos lipófilos y método para su preparación
CA2737543C (en) * 2008-09-19 2015-01-06 Activus Pharma Co., Ltd. Composite organic compound powder for medical use and production method and suspension of the same
FR2940118B1 (fr) 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
KR20110117145A (ko) * 2009-01-30 2011-10-26 메이지 세이카 파루마 가부시키가이샤 미분쇄 약제학적 조성물
MX2011013726A (es) * 2009-06-19 2012-02-29 Sun Pharma Advanced Res Co Ltd Nanodispersión de un medicamento y proceso para su preparación.
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
CN103284952A (zh) * 2012-02-29 2013-09-11 北京万生药业有限责任公司 一种含有非诺贝特的药物组合物
CN103211759B (zh) * 2013-03-28 2015-07-08 中国人民解放军军事医学科学院毒物药物研究所 葛根素纳米晶药用组合物及其制备方法
KR101344218B1 (ko) * 2013-05-15 2013-12-20 충남대학교산학협력단 페노피브레이트를 함유하는 결핵 치료용 약학 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
KR101850119B1 (ko) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) 생체이용률이 향상된 신규한 페노피브르산 전구약물
CN105616369A (zh) * 2016-03-29 2016-06-01 河北科技大学 溶出增强型非诺贝特片的制备方法
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JPWO2019004447A1 (ja) 2017-06-30 2020-04-30 興和株式会社 医薬組成物
KR102081095B1 (ko) * 2018-04-24 2020-02-25 한국유나이티드제약 주식회사 페노피브릭산 또는 이의 약학적으로 허용 가능한 염을 포함하는 장용성 코팅 정제
CN112236141A (zh) 2018-06-11 2021-01-15 大塚制药株式会社 包含德拉马尼的组合物
DK3928772T3 (da) 2020-06-26 2024-08-19 Algiax Pharmaceuticals Gmbh Nanopartikulær sammensætning
KR102369827B1 (ko) * 2020-09-04 2022-03-04 (주)피알지에스앤텍 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법
WO2022071768A1 (en) * 2020-09-29 2022-04-07 Addpharma Inc. A pharmaceutical composition comprising fenofibrate particles with improved bioavailability
CN118401235A (zh) * 2021-12-08 2024-07-26 Prg科技株式会社 含有Progerinin的纳米悬浮液及其制备方法
KR102686558B1 (ko) * 2022-01-25 2024-07-22 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제
KR20240108664A (ko) 2023-01-02 2024-07-09 주식회사 다산제약 생체 이용률이 개선된 페노피브레이트를 포함하는 약학 조성물

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907792A (en) * 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU2317592A (en) * 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
DE69633222T2 (de) * 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
FR2761912B1 (fr) * 1997-04-14 1999-07-02 Capsulis Procede destine a faire adherer un produit sur une surface
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
AU1809499A (en) * 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
KR100628341B1 (ko) * 1998-03-30 2006-09-27 스키에파마 캐나다 인코포레이티드 수-불용성 물질의 미소입자 조성물 및 이의 제조방법
WO1999065469A2 (en) * 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6431478B1 (en) * 1999-06-01 2002-08-13 Elan Pharma International Limited Small-scale mill and method thereof
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
AU2001257115B2 (en) * 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
CN1211164C (zh) * 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
AU8847101A (en) * 2000-08-31 2002-03-13 Rtp Pharma Inc Milled particles
WO2002024169A1 (en) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US20030224058A1 (en) 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations

Also Published As

Publication number Publication date
EP1519715A2 (en) 2005-04-06
US20030224058A1 (en) 2003-12-04
UY38044A (es) 2020-05-29
WO2004041250A3 (en) 2004-10-21
PT1519715T (pt) 2023-06-14
EA023686B1 (ru) 2016-07-29
CN1668281A (zh) 2005-09-14
AU2003301807A1 (en) 2004-06-07
EA200900485A1 (ru) 2010-04-30
EP1519715B1 (en) 2023-02-22
KR20120057664A (ko) 2012-06-05
CA2487054A1 (en) 2004-05-21
AU2008264174A1 (en) 2009-01-29
MXPA04011653A (es) 2005-07-27
JP4395074B2 (ja) 2010-01-06
IL165332A (en) 2015-07-30
CN101797245A (zh) 2010-08-11
JP2006508105A (ja) 2006-03-09
UY27822A1 (es) 2003-12-31
AU2003301807B2 (en) 2008-09-25
SG159391A1 (en) 2010-03-30
IL165332A0 (en) 2006-01-15
JP2010013462A (ja) 2010-01-21
CA2487054C (en) 2008-03-18
NZ537324A (en) 2007-06-29
EA012842B1 (ru) 2009-12-30
KR101300654B1 (ko) 2013-08-28
KR101216853B1 (ko) 2012-12-28
NO20050224L (no) 2005-01-14
MA27250A1 (fr) 2005-03-01
BRPI0311275A2 (pt) 2016-06-28
TNSN04230A1 (en) 2007-03-12
AU2003301807B9 (en) 2021-04-01
EA200401556A1 (ru) 2005-10-27
MY143202A (en) 2011-03-31
KR20050026705A (ko) 2005-03-15
CN101797233A (zh) 2010-08-11
KR20110116252A (ko) 2011-10-25
TW200403079A (en) 2004-03-01
AU2008264174B2 (en) 2011-04-07
CN101797245B (zh) 2018-01-02
ES2946493T3 (es) 2023-07-19
TWI347198B (en) 2011-08-21
WO2004041250A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AR040110A1 (es) Formulaciones de fibrato en nanoparticulas
DE602004021107D1 (de) Meloxican-formulierungen in nanoteilchenform
ES2526092T3 (es) Formulaciones de olanzapina en nanopartículas inyectables
ATE487470T1 (de) Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
ES2164098T3 (es) Composiciones farmaceuticas que contienen una proteina bactericida aumentadora de la permeabilidad y un tensioactivo.
EA200701274A1 (ru) Нанодисперсные составы на основе такролимуса
BRPI0518772A2 (pt) formulaÇÕes de benzotiofeno em nanopartÍcula
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
AR032394A1 (es) Una composicion oral.
AR038308A1 (es) Composiciones cosmeticas o para el cuidado personal
TW200636025A (en) Light stabilizer emulsion composition
TW200611712A (en) Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
ATE521324T1 (de) Transparenteabdeckende kosmetikzusammensetzungen
ATE395042T1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
WO2007064912A3 (en) Mometasone compositions and methods of making and using the same
AR026304A1 (es) Proceso para la produccion de composiciones para el cuidado oral mediante el uso de polimeros dispersables aglomerados.
BR0213608A (pt) Composição oral
ATE422880T1 (de) Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
DE502006000883D1 (de) Kunststoffformkörper mit durch laser-innengravur erzeugten zwei- oder dreidimensionalen bildstrukturen
BRPI0419048A (pt) composição útil para fornecer revestimento de remoção de nox sobre a superfìcie material
ATE422155T1 (de) Nanopartikelzusammensetzungen enthaltend fenofibrat
JP2005525451A5 (es)
ATE446742T1 (de) Nanopartikuläre ebastinformulierungen

Legal Events

Date Code Title Description
FC Refusal